Medtronic PLC · pre-call briefing
Reports 2026-09-01. The record: 216 graded commitments, beat rate 27%, median surprise +0.6%, severity-weighted accuracy 77.7. Restatements count once.
1 · Questions worth asking
1. On the CAS target underlying #40734, can you break out how much of the incremental $1 billion is expected to come from installed-base pull-through versus new placements, and what quarterly run-rate is needed by FY27 to stay on schedule?
Basis: #40734, resolving this call
2. You said Hugo 'may not move the needle on the surgical business quite yet,' a shift from expecting it to be a growth driver in FY26. What specific variable, unit placements, procedure mix, or capital sales cycle, moved, and what level of that variable would bring surgical growth back on track?
Basis: walk-back #40624
3. On the diabetes commitment to hold revenue per patient and gross margin neutral while presumably shifting mix, what's the underlying assumption on channel or geographic mix that makes that margin-neutral math work?
Basis: #40527, operational/peripheral tier
2 · The CEO on the record
Counted, never scored; commitments without a checkable bar.
2026-02-17 · “But underneath the covers there, Hugo is growing and growing pretty fast now. And it will -- eventually, you'll see -- you'll start to see this move that big $6 billion business.”
2026-02-17 · “Now this is going to be a contributor for years to come given the 18 million U.S. patients with uncontrolled hypertension.”
2026-02-17 · “These are all real drivers with tangible reasons for improvement and the potential to impact growth in the coming quarters and years.”
3 · Resolving on this call: 3
OPENVERDICTDeadline not reached yet; the claim is still on the clock.coremarginsCONVICTIONStated expectation · “we expect”, “should”, “we see”
“We're making progress on margin expansion, and the negative mix effect from CAS and Diabetes are going to get better.”
WHAT TO LOOK FOR
Company gross margin (and/or operating margin), reported quarterly, with commentary on CAS and Diabetes mix impact
Second-half fiscal 2026 (Q3+Q4) gross margin and operating margin ex-tariffs higher than first-half fiscal 2026 levels, with management citing improved CAS/Diabetes mix contribution SourceWHERE TO FIND ITCompany quarterly income statement and earnings call management commentary (Medtronic Q3/Q4 FY26 results)KNOWABLE AFTER2026-05-31
OPENVERDICTDeadline not reached yet; the claim is still on the clock.operationalgrowthCONVICTIONHigh conviction · “confident”, “clear line of sight”, absolute language
“When I said that, we're sticking to that. Nothing's changed.”
WHAT TO LOOK FOR
Cumulative Annual CAS (Cardiac Ablation Solutions) sales growth on top of FY'25 base, as disclosed by Medtronic
CAS annual sales reach FY'25 base + $1 billion, achieved by FY2027 (i.e., no later than fiscal year ending April 2027) SourceWHERE TO FIND ITMedtronic quarterly/annual earnings reports and management commentary (10-K/10-Q, earnings calls)KNOWABLE AFTER2027-04-30
OPENVERDICTDeadline not reached yet; the claim is still on the clock.operationalgrowthCONVICTIONHigh conviction · “confident”, “clear line of sight”, absolute language
“And we continue to have near-term line of sight to adding an incremental $1 billion in revenue off of our fiscal '25 base.”
WHAT TO LOOK FOR
Cumulative incremental revenue added to CAS (cardiac ablation solutions) business relative to fiscal 2025 base revenue
Incremental CAS revenue >= $1 billion above fiscal '25 base SourceWHERE TO FIND ITCompany segment revenue disclosure (10-K/10-Q or earnings call commentary on CAS revenue)KNOWABLE AFTER2027-04-30
4 · Guidance in flight, expect an update: 6
These periods have not concluded, so nothing resolves here; management addresses each by reaffirming, raising, or cutting it.
OPENVERDICTDeadline not reached yet; the claim is still on the clock.coremarginsCONVICTIONStated expectation · “we expect”, “should”, “we see”
“Upon separation, we continue to expect approximately 50 basis points of gross margin improvement and 100 basis points of operating margin improvement.”
WHAT TO LOOK FOR
Company-wide adjusted gross margin and operating margin, measured after completion of MiniMed separation, relative to pre-separation baseline
Gross margin improvement >= 50 basis points AND operating margin improvement >= 100 basis points versus pre-separation levels SourceWHERE TO FIND ITCompany financial statements / management commentary on post-separation earnings callKNOWABLE AFTER2026-11-19
OPENVERDICTDeadline not reached yet; the claim is still on the clock.corecapital allocationCONVICTIONStated expectation · “we expect”, “should”, “we see”
“Given the share retirement, this separation is expected to be immediately accretive to Medtronic EPS upon completion.”
WHAT TO LOOK FOR
Medtronic adjusted (non-GAAP) EPS, comparing the quarter immediately following separation completion to the same quarter's pre-separation run rate/prior-year comparable
Adjusted EPS impact from the separation (as disclosed by management) is positive, i.e., accretive, in the first reporting period after completion SourceWHERE TO FIND ITMedtronic quarterly earnings release and management commentary on the earnings call following separation completionKNOWABLE AFTER2026-11-21
OPENVERDICTDeadline not reached yet; the claim is still on the clock.coremarginsCONVICTIONStated expectation · “we expect”, “should”, “we see”
“So, upon full separation, we’re expecting our adjusted gross and operating margins to improve by approximately 50 and 100 basis points, respectively.”
WHAT TO LOOK FOR
Change in Medtronic adjusted gross margin and adjusted operating margin (company-reported, non-GAAP) versus pre-separation baseline, measured upon completion of the Diabetes separation
Adjusted gross margin improves by approximately 50 basis points (40-60 bps) and adjusted operating margin improves by approximately 100 basis points (80-120 bps) versus the last reported figures prior to separation SourceWHERE TO FIND ITMedtronic quarterly earnings release / 10-Q or 10-K non-GAAP reconciliation and management commentary on earnings call following completion of separationKNOWABLE AFTER2026-11-21
OPENVERDICTDeadline not reached yet; the claim is still on the clock.corecapital allocationCONVICTIONStated expectation · “we expect”, “should”, “we see”
“And then the Diabetes deal, we fully expect the deal to be accretive.”
WHAT TO LOOK FOR
EPS accretion/dilution impact from the Diabetes business separation deal, as disclosed by management
Diabetes deal reported as accretive to EPS (post-separation), consistent with management's full-year EPS guidance build SourceWHERE TO FIND ITCompany earnings release / management commentary on quarterly earnings calls (MDT)KNOWABLE AFTER2026-12-31
OPENVERDICTDeadline not reached yet; the claim is still on the clock.coregrowthCONVICTIONHigh conviction · “confident”, “clear line of sight”, absolute language
“So I think we feel good about the growth continuing here out not just in Q4, but into FY '27.”
WHAT TO LOOK FOR
Company total revenue organic growth rate, quarterly (Q4 FY26) and full fiscal year FY27
Q4 FY26 organic revenue growth > FY25 comparable growth rate reported, and FY27 full-year organic revenue growth rate positive and in line with or above previously guided range SourceWHERE TO FIND ITCompany quarterly earnings release and 10-K/10-Q revenue disclosures (Q4 call and FY27 annual results)KNOWABLE AFTER2027-04-30
OPENVERDICTDeadline not reached yet; the claim is still on the clock.coregrowthCONVICTIONStated expectation · “we expect”, “should”, “we see”
“Look, first, it's a little bit less than 2 points of full growth. And again, we'll give you the specific calculations as we close the year, but the way to think of it is that there's going to be growth acceleration, excluding the extra week, right? So it should be upside.”
WHAT TO LOOK FOR
Organic revenue growth rate for fiscal year 2027, excluding the extra week contribution
FY2027 organic growth (ex-extra week) higher than FY2026 organic growth rate SourceWHERE TO FIND ITCompany-reported organic revenue growth disclosure (10-K/earnings release/call commentary)KNOWABLE AFTER2027-05-31
5 · Walked back recently
REVISED DOWN
“And, you know, as we look to FY ‘26, Hugo accelerates and becomes more of a growth driver for surgical at the surgical level.”
THEN
“The surgical business is a big business, has some puts and takes. So you may not move the needle on the surgical business quite yet.”
REVISED DOWN
“Now in the US, we received FDA approval for Simplera Sync just last month and expect to begin the launch this fall.”
THEN
“As that ramp continues, we plan to roll it out more broadly to U.S. consumers later this fiscal year.”
REVISED DOWN
“Now we expect that Surgical will return to more normalized growth in the back half of the fiscal year as these comparisons ease.”
THEN
“We expect this to resolve as we start fiscal ‘26.”
REVISED DOWN -9.1%
“Based on recent rates, FX would have an unfavorable impact to fiscal '25 in the range of $225 million to $325 million, including $100 million to $150 million in the third quarter.”
THEN
“Based on recent rates, FX would have an impact to fiscal ‘25 in the range of $275 million to $325 million, including $125 million to $175 million in the fourth quarter.”
Method: methodology 4.0. Every grade carries its verbatim source; abstention is disclosed, never guessed.